Trials / Terminated
TerminatedNCT00837824
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
A Phase 2, Randomized, Open Label, Dose-Ranging, Multiple Dose Study of Fabrazyme® In Patients With Fabry Disease and With Severe Renal Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to determine appropriate treatment with Fabrazyme at a biweekly dose of either 1 mg/kg or 3 mg/kg in a population of patients with severe renal disease burden.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Fabrazyme (agalsidase beta) | 1.0 mg/kg every 2 weeks |
| BIOLOGICAL | Fabrazyme (agalsidase beta) | 3.0 mg/kg every 2 weeks |
Timeline
- Start date
- 2002-12-01
- Primary completion
- 2003-08-01
- Completion
- 2003-08-01
- First posted
- 2009-02-05
- Last updated
- 2015-04-07
- Results posted
- 2009-02-05
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00837824. Inclusion in this directory is not an endorsement.